Online Mindfulness-based Cognitive Therapy for Parents of Children With Food Allergies
Launched by CANTERBURY CHRIST CHURCH UNIVERSITY · Feb 1, 2021
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
This study is a pilot randomised controlled trial (RCT) comparing adapted, live online, mindfulness-based cognitive therapy for parents and carers of children with food allergies (MBCT-PCCFA) with a treatment as usual control. A battery of self-report measures will be administered online at baseline (week 0), post-intervention (week 15) and at follow-up (week 23).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Parents or caregivers who identify as having a child under the age of 18 with a food allergy
- • The allergy has been diagnosed by a qualified physician (e.g. GP or allergy specialist)
- • Mean score of \>=2 on the FAQL-PB, indicating they are at least 'somewhat limited/troubled' by their child's allergy (Cohen et al., 2004).
- • Resident in the United Kingdom
- • Have access to email, a PC/laptop/tablet with a webcam and microphone and internet access to allow videoconferencing
- Exclusion Criteria:
- • They had consulted on the design and content of the intervention or study
- • They have already participated in a substantial mindfulness-based course
- • They are currently engaged or are planning to engage with another psychological intervention during the course of the study
- • They currently engage in regular mindfulness-based practice
- • They do not have the practical means and time available to be able to attend the intervention during the dates outlined on the information sheet and commit to at-home practice
- • They have scores \>19 on PHQ-8 (indicating 'severe' depressive symptom severity; Kroenke et al., 2009) or \>15 on GAD (indicating 'severe' level of anxiety; Spitzer et al., 2006)
- • They have a problem with alcohol or recreational drug misuse
- • They have experienced thoughts about harming themselves or others in the last 12 months
- • They have been given a diagnosis of psychosis
- • They are currently experiencing high levels of distress and/or currently feeling particularly fragile
- • They have experienced a bereavement of someone close to them in the last year or are continuing to experience continuing grief in relation to losing someone further back in time
- • They have had traumatic experiences that they continue to be troubled by (including, but not limited to, receiving diagnosis of post-traumatic stress disorder)
- • They experience significant difficulty being in a group with other people.
- • NB: for further details re the FAQL-PB and PHQ-8, please see the outcome measures section.
About Canterbury Christ Church University
Canterbury Christ Church University is a leading higher education institution in the UK, renowned for its commitment to research excellence and community engagement. With a strong focus on health and social care, the university undertakes a range of clinical trials aimed at advancing medical knowledge and improving patient outcomes. By leveraging interdisciplinary collaboration and state-of-the-art facilities, Canterbury Christ Church University strives to contribute valuable insights to the scientific community while fostering innovation in healthcare practices. Its dedicated team of researchers and practitioners work diligently to ensure the highest standards of ethical conduct and scientific rigor in all clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tunbridge Wells, Kent, United Kingdom
Patients applied
Trial Officials
Ellie Craig, MSc
Principal Investigator
Canterbury Christ Church University
Fergal Jones, PhD, PsychD
Study Director
Canterbury Christ Church University
Christina Jones, PhD
Study Director
University of Surrey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials